Matthew Chrzanowski
Overview
Explore the profile of Matthew Chrzanowski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
177
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang X, Chrzanowski M, Liu Y
J Vis Exp
. 2024 May;
(206).
PMID: 38709074
Utilizing vegetable oil as a sustainable feedstock, this study presents an innovative approach to ultrasonic-assisted transesterification for biodiesel synthesis. This alkaline-catalyzed procedure harnesses ultrasound as a potent energy input, facilitating...
2.
Zhang J, Yu X, Chrzanowski M, Tian J, Pouchnik D, Guo P, et al.
Mol Ther Methods Clin Dev
. 2024 Mar;
32(1):101215.
PMID: 38463141
The unique palindromic inverted terminal repeats (ITRs) and single-stranded nature of adeno-associated virus (AAV) DNA are major hurdles to current sequencing technologies. Due to these characteristics, sequencing noncanonical AAV genomes...
3.
Zhang J, Frabutt D, Chrzanowski M, Li N, Miller L, Tian J, et al.
Mol Ther Methods Clin Dev
. 2024 Feb;
32(1):101206.
PMID: 38390555
Self-complementary AAV vectors (scAAV) use a mutant inverted terminal repeat (mITR) for efficient packaging of complementary stranded DNA, enabling rapid transgene expression. However, inefficient resolution at the mITR leads to...
4.
Li X, Miller L, Chrzanowski M, Tian J, Jarrold M, Herzog R, et al.
Front Bioeng Biotechnol
. 2024 Jan;
11:1327433.
PMID: 38173872
Genetic engineering advances have led to recombinant adeno-associated virus (rAAV) becoming an invaluable tool for the development of effective gene therapies. The production of rAAV is susceptible to off-target heterogeneous...
5.
Lam A, Mulcrone P, Frabutt D, Zhang J, Chrzanowski M, Arisa S, et al.
Adv Cell Gene Ther
. 2023 Dec;
2023.
PMID: 38130431
Recombinant adeno-associated viruses (AAVs) have emerged as a widely used gene delivery platform for both basic research and human gene therapy. To ensure and improve the safety profile of AAV...
6.
Mulcrone P, Lam A, Frabutt D, Zhang J, Chrzanowski M, Herzog R, et al.
Sci Rep
. 2023 May;
13(1):8436.
PMID: 37231038
Although more adeno-associated virus AAV-based drugs enter the clinic, vector tissue tropism remains an unresolved challenge that limits its full potential despite that the tissue tropism of naturally occurring AAV...
7.
Zhang J, Chrzanowski M, Frabutt D, Lam A, Mulcrone P, Li L, et al.
J Med Virol
. 2022 Dec;
95(1):e28433.
PMID: 36571262
Recombinant adeno-associated virus (rAAV) vectors carry a cassette of interest retaining only the inverted terminal repeats (ITRs) from the wild-type virus. Conventional rAAV production primarily uses a vector plasmid as...
8.
Zhang J, Guo P, Yu X, Frabutt D, Lam A, Mulcrone P, et al.
Mol Ther Nucleic Acids
. 2022 Sep;
29:852-861.
PMID: 36159586
Recombinant adeno-associated virus (rAAV) vectors have been developed for therapeutic treatment of genetic diseases. Current rAAV vectors administered to affected individuals often contain vector DNA-related contaminants. Here we present a...
9.
Xu Y, Guo P, Zhang J, Chrzanowski M, Chew H, Firrman J, et al.
Mol Ther Methods Clin Dev
. 2020 Jul;
18:328-334.
PMID: 32671135
Physical titers for recombinant adeno-associated viral (rAAV) vectors are measured by quantifying viral genomes. It is generally perceived that AAV virions disassemble and release DNA upon thermal treatment. Here, we...
10.
Guo P, Zhang J, Chrzanowski M, Huang J, Chew H, Firrman J, et al.
Mol Ther Methods Clin Dev
. 2019 Jan;
13:40-46.
PMID: 30623003
Recombinant adeno-associated virus (rAAV) has been developed as a successful vector for both basic research and human gene therapy. However, neutralizing antibodies (NAbs) against AAV capsids can abolish AAV infectivity...